Show me the money: Which drugs made the top 10 list on upfront deals?

 

 

Show me the money: Which drugs made the top 10 list on upfront deals?

Read more: Show me the money: Which drugs made the top 10 list on upfront deals? – FierceBiotech http://www.fiercebiotech.com/story/show-me-money-which-drugs-made-top-10-list-upfront-deals/2014-05-12#ixzz31ZXkIoPl
Subscribe at FierceBiotech

Advertisements

Lilly draws flak after touting PhIII diabetes success for Lantus rival May 12, 2014

 

Lilly draws flak after touting PhIII diabetes success for Lantus rival

Eli Lilly ($LLY) says its experimental diabetes therapy basal insulin peglispro beat out Sanofi’s ($SNY) blockbuster Lantus for reducing levels of HbA1c in a trio of late-stage trials. But at least one prominent analyst swiftly raised questions about potential safety issues for this Lantus rival, which hopes to bite off a big piece of the market as Sanofi settles in for a lengthy legal battle to protect one of its bestselling products.

Read more: Lilly draws flak after touting PhIII diabetes success for Lantus rival – FierceBiotech http://www.fiercebiotech.com/story/lilly-draws-flak-after-touting-phiii-diabetes-success-lantus-rival/2014-05-12#ixzz31ZWtUqh5
Subscribe at FierceBiotech

Read more: Lilly draws flak after touting PhIII diabetes success for Lantus rival – FierceBiotech http://www.fiercebiotech.com/story/lilly-draws-flak-after-touting-phiii-diabetes-success-lantus-rival/2014-05-12#ixzz31ZWL50zi
Subscribe at FierceBiotech

An Aspirin a Day? Only If You Have Had a Heart Attack

aspirin

An Aspirin a Day? Only If You Have Had a Heart Attack FDA issues recommendation against preventative low doses

By Steven Nissen, MD | 5/12/14 1:01 p.m

More Read :

http://health.clevelandclinic.org/2014/05/an-aspirin-a-day-only-if-you-have-had-a-heart-attack/

Scientists discover spiderman in all of us

Spiders are ecologically important predators with complex venom and extraordinarily tough silk that enables capture of large prey. Here we present the assembled genome of the social velvet spider and a draft assembly of the tarantula genome that represent two major taxonomic groups of spiders. The spider genomes are large with short exons and long introns, reminiscent of mammalian genomes. Phylogenetic analyses place spiders and ticks as sister groups supporting polyphyly of the Acari. Complex sets of venom and silk genes/proteins are identified. We find that venom genes evolved by sequential duplication, and that the toxic effect of venom is most likely activated by proteases present in the venom. The set of silk genes reveals a highly dynamic gene evolution, new types of silk genes and proteins, and a novel use of aciniform silk. These insights create new opportunities for pharmacological applications

More read

http://www.nature.com/ncomms/2014/140506/ncomms4765/full/ncomms4765.html

Otsuka multi-drug resistant TB drug approved in Europe

 

Delamanid.svg

Otsuka Pharmaceutical Co has been given the green light to sell its tuberculosis drug Deltyba in Europe.

 

Otsuka multi-drug resistant TB drug approved in Europe.

Antibiotic May Sidestep Resistance, Drug Discovery: Bacteria may find agent’s mechanism hard to circumvent.

Rifamycin SV (yellow structure) and GE23077 (blue structure) bind to adjacent sites on RNA polymerase (red and yellow), and a combination of the two is a bacterial resistance-resistant drug lead.

Rifamycin SV (yellow stick structure) and GE23077 (blue stick structure) bind to adjacent sites on RNA polymerase (red and green). Mesh indicates electron density; purple ball is active site’s magnesium ion.

Antibiotic May Sidestep Resistance

Drug Discovery: Bacteria may find agent’s mechanism hard to circumvent.

Researchers finally know exactly how the promising antibiotic GE23077 (GE) inhibits an essential bacterial enzyme. They predict that GE’s ability to hit this enzyme in its active site could make it difficult for bacteria to develop resistance to the agent. The study also shows how GE might be conjugated with another antibiotic to make a combination drug the scientists believe might be unusually resistance-proof.

 

Antibiotic May Sidestep Resistance, Drug Discovery: Bacteria may find agent’s mechanism hard to circumvent..

Semagacestat

Semagacestat structure.svg

Semagacestat (LY450139) was a candidate drug for a causal therapy against Alzheimer’s disease. It was originally developed by Eli Lilly and Élan, and clinical trials were conducted by Eli Lilly. Phase III trials included over 3000 patients,[2][3] but in August 2010, a disappointing interim analysis, in which semagacestat performed worse than the placebo, led to the trials being stopped.

More read

Semagacestat.

World Drug Tracker: DASABUVIR, ABT 333 for the chronic Hepatitis C treatment. « New Drug Approvals

World Drug Tracker: DASABUVIR, ABT 333 for the chronic Hepatitis C treatment. « New Drug Approvals.

Tanzeum New FDA Drug Approval | CenterWatch

 

 

Tanzeum New FDA Drug Approval | CenterWatch.

Albiglutide

From Wikipedia, the free encyclopedia
 
Jump to: navigation, search
Albiglutide
Clinical data
Legal status Investigational
Pharmacokinetic data
Half-life 4-7 days
Identifiers
CAS number 782500-75-8
ATC code None
Chemical data
Formula C3232H5032N864O979S41 
Mol. mass 72,970 g/mol

Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug under investigation by GlaxoSmithKline for treatment of type 2 diabetes. It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin.

Albiglutide has a half-life of four to seven days, which is considerably longer than the other two GLP-1 analogs approved for market use, exenatide (Byetta) and liraglutide (Victoza).[1] [2] GLP-1 drugs are currently only available for subcutaneous administration on a daily basis, so a GLP-1 drug with a longer half-life is desirable. Such a drug would only need to be injected biweekly or weekly instead of daily, reducing the discomfort and inconvenience of GLP-1 administration considerably.

It has not yet been determined whether albiglutide is as effective an antidiabetic agent as GLP-1 drugs currently on the market, and final data remains to be published regarding the incidence of adverse effects related to the drug. To evaluate the efficacy and safety of the drug, albiglutide is undergoing eight Phase III clinical trials. Four of these trials should report useful data by end 2010.[3][dated info]6 GSK filed for FDA approval on 01/14/2013 and European Medical Agency (EMA) on 03/07/2013. On 08/02/2013 GSK released a press release pushing the marketing date 3 months to 04/15/2014.

In March 2014, GlaxoSmithKline PLC received approval from the European Commission to market albiglutide under the name ‘Eperzan’. [4]

In April 2014, the FDA approved albiglutide under the name Tanzeum.[5]

Bristol-Myers Squibb ranks first on 2014 Best Corporate Citizens List

 

Bristol-Myers Squibb ranks first on 2014 Best Corporate Citizens List.